In aggregate, US, European, Canadian and Australian biotech companies recorded a $3.7 billion net profit in 2009, making it the first profitable year for the industry. However, raising capital remained difficult, with a few established companies gaining the bulk of new capital. Capital raised by US biotech firms rose 39% to $18.0 billion. Revenues for publicly listed biotech companies in these countries grew 8%, excluding Genentech, which was acquired. For US companies, excluding Genentech, revenues grew 9.5%. For European companies, revenues grew 8%. Venture capital raised by US and European biotech companies totaled $4.6 billion and €800 million ($1.1 billion), respectively.

Source: Ernst & Young